PCSK9s stalk Merck's Vytorin

November 18, 2014 8:32 PM

12 0

PCSK9s stalk Merck's Vytorin

Monday's Vytorin news gave Merck a little bit of breathing room, but the respite appears to be short-lived.

The reason: the results were presented at the American Heart Association's Scientific Sessions the very same day Sanofi and Regeneron unveiled results of a head-to-head study comparing the companies' experimental PCSK9, alirocumab, to Merck's Zetia (ezetimibe), which is one half of its cholesterol-l...

Read more

To category page